Lund, Sweden, April 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company's Board member Carl Borrebaeck, who has declined re-election ahead of the Annual General Meeting on June 1, 2021, has resigned from the Board of Directors at his own request.
Carl Borrebaeck is a co-founder of Alligator and has played a significant role in the company's development and positioning as one of the leading companies in immuno-oncology. Carl Borrebaeck has been a Board member of Alligator since the company was founded in 2001.
For further information, please contact:
Marie Svensson, CFO
Phone: +46 46 540 82 03
E-mail: marie.svensson@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact person set out above, at 9:40 a.m. CET on April 30, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.